Replies

This one isn’t a poser.

Katalin Karikó
https://en.wikipedia.org/wiki/Katalin_Kariko

“Katalin Karikó (Hungarian: Karikó Katalin, Hungarian pronunciation: [ˈkɒrikoː ˌkɒtɒlin]; born 17 January 1955) is a Hungarian biochemist who specializes in RNA-mediated mechanisms. Her research has been the development of in vitro-transcribed mRNA for protein therapies. She co-founded and was CEO of RNARx, from 2006 to 2013.[1] Since 2013, she has been a vice president and promoted to senior vice president in 2019 at BioNTech RNA Pharmaceuticals.[2] She is also an adjunct professor at the University of Pennsylvania.[1]

Karikó’s work includes the scientific research of RNA-mediated immune activation, resulting in the co-discovery with American immunologist Drew Weissman of the nucleoside modifications that suppress the immunogenicity of RNA.[3][4][5] This is seen as permitting the therapeutic use of mRNA.[6] Together with Weissman, she holds U.S. patents for the application of non-immunogenic, nucleoside-modified RNA. This technology has been licensed by BioNTech and Moderna to develop their COVID-19 vaccines.[7]...

Scientific contributions
The work and research of Karikó has contributed to BioNTech’s effort to create immune cells that produce vaccine antigens — her research revealed that the antiviral response from mRNA gave their cancer vaccines an extra boost in defense against tumors.[2] In 2020, Karikó’s and Weissman’s technology was used within a vaccine for COVID-19 that was produced jointly by Pfizer and BioNTech.[6][10] The British ethologist Richard Dawkins, as well as the Canadian stem cell biologist Derrick Rossi, who helped found Moderna, have called for these two to receive a Nobel Prize.[12][13][14]...”